機構股票研究
機構股票研究
機構股票研究
機構股票研究 
 
Page | 1 | PHILLISECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ) 
混改加速發展 
 
中國大陸
中國大陸
中國大陸
中國大陸| 醫藥
醫藥
醫藥
醫藥 | 公司研報
公司研報
公司研報
公司研報 
 
 
 
17 April 2018 
 
投資概要
投資概要
投資概要
投資概要 
 
公司醫藥商業實現平穩增長，醫藥工業方面，健康產品增長顯著。銷售費用大幅上
升，行銷力度不斷加大。混改進一步落地，有望進一步激發未來增長動力。考慮到銷
售費用等支出可能增加，我們調低2018年EPS預測至3.4元/股（原3.55元/股）。對比歷
史市盈率和行業市盈率水準，我們給予33倍目標市盈率，目標股價112.0元。(現價截至
4月13日) 
 
公司概
公司概
公司概
公司概況 
 
混改加速發展
混改加速發展
混改加速發展
混改加速發展 
2017年，公司控股股東雲南白藥控股有限公司引進民營企業新華都和江蘇魚躍作為戰
略投資者，白藥控股股權結構變更為雲南省國資委、新華都與江蘇魚躍分別持有
45%、45%、10%股權，白藥控股及上市公司均變更為無實際控制人企業。經過2017年
調整之後，我們期望2018年這種混改方式進一步激發企業活力，提升企業競爭力。 
 
醫藥商業平穩增長
醫藥商業平穩增長
醫藥商業平穩增長
醫藥商業平穩增長 
省醫藥公司實現收入14,494百萬元，同比增長7.5%。我們預計，2018年隨著兩票制的
影響進一步消化，商業板塊有望優化。醫藥商業基本實現雲南縣級以上及部分發達鄉
鎮醫院全覆蓋；同時探索線下零售藥店業務、藥房託管、網上售藥等線上線下管道協
同發展。公司目前實現主要電商平臺全覆蓋，同時，開展在微商等領域內的管道建設
探索。 
 
醫藥工業個別發展
醫藥工業個別發展
醫藥工業個別發展
醫藥工業個別發展 
醫藥工業收入整體實現同比增長9.7%。(1)藥品事業部收入達到5,043.5百萬元，同比增
長2.56%，表現相對疲弱。公司根據兩票制等醫改政策調整分銷模式，確保產品分銷的
合規性。產品方面，針對藥用消費品消費需求增長的趨勢，篩選內部批文資源，推動
藥用消費品產品體系建設；加快蒸汽眼罩等護理類工業產品的研發和推廣。(2)健康產
品部實現收入4,361.1百萬元，同比增長16%，健康產品管道已實現全國覆蓋，部分發
達地區實現縣鄉一級覆蓋。同時，公司積極發展電子商務，在杭州成立互聯網行銷中
心，以旗艦店形式入駐各大電商平臺。 
 
把握時代行銷特點
把握時代行銷特點
把握時代行銷特點
把握時代行銷特點 
公司的銷售費用同比上升30%，主要是由於市場維護和推廣費用增加。公司重點部署
在互聯網管道、樓宇管道以及年輕消費群體關注的活動賽事冠名等新型媒體傳播管
道，提升公司品牌在年輕消費人群中的知名度。採用事件型行銷增加產品曝光度，結
合熱門IP，推出相應產品，2017年公司借助熱門影視劇集“三生三世十裡桃花”和
“春風十裡不如你”推出雲南白藥養元青十裡桃花限量定制系列和雲南白藥春風十裡
定制款洗漱包；自主打造大IP運動賽事“雲南白藥愛跑538”，陸續與長沙、重慶、武
漢等地的合作夥伴共同組織開展活動。隨著在行銷方面的投入增大，我們預計2018、
2019年的銷售費用仍可能呈上升趨勢。 
 
 
 
 
增持
增持
增持
增持 
現價 RMB96.22 
(現價截至4 月13 日) 
目標價 RMB112.0 (+16.4%) 
 
公司資料
公司資料
公司資料
公司資料 
普通股股東 (百萬股) : 
1,041.4
市值 (人民幣百萬元) : 
100,203
52 周 最高價/最低價 (人民幣) : 
109.87/81.03
 
 
主要股東
主要股東
主要股東
主要股東， % 
Yunnan Baiyao Holdings 
41.52
Yunnan Hehe 
10.09
Pingan 
9.36
HK Connect 
6.51
New Huadu 
3.39
CSF 
2.56
 
股價表現
股價表現
股價表現
股價表現% 
1 個月
個月
個月
個月
3 個月
個月
個月
個月
1 年
雲南白藥 
1.38 
5.53 
14.03 
上證指數 
-3.50 
-6.49 
-2.68 
 
股價
股價
股價
股價 & 上證指數
上證指數
上證指數
上證指數 
 
Source: Aastocks, Phillip Securities (HK) Research 
 
財務資料
財務資料
財務資料
財務資料 
RMB/mn 
FY16
FY17
FY18E
FY19E
Net Sales 
22,411
24,315
26,911
29,263
Net Profit 
2,931
3,133
3,536
4,005
EPS, RMB 
2.80 
3.02 
3.40 
3.85 
PER, x 
34.36 
31.86 
28.34 
25.02 
BVPS, RMB
15.10 
17.32 
19.97 
22.85 
P/BV, x 
6.37 
5.56 
4.82 
4.21 
ROE, %  
18.50 
17.27 
17.00 
16.83 
Source: Wind, Phillip Securities Est. 
 
周霖
周霖
周霖
周霖 (2277 6515) 
euruszhou@phillip.com.hk 
 
 
 
 
 
 
 
 
Page | 2 | PHILLISECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ)
公司研報
公司研報
公司研報
公司研報 
估值和風險
估值和風險
估值和風險
估值和風險 
 
我們的模型顯示目標價為
我們的模型顯示目標價為
我們的模型顯示目標價為
我們的模型顯示目標價為112.0元。我們預測未來各分部業務增速，並且考慮到
銷售費用等支出可能增加，調低2018年EPS預測至3.4元/股（原3.55元/股）。中
藥行業目前合理估值水準在33.5-37.6倍左右（市盈率中位數、平均數），對比歷
史市盈率和行業估值，我們給予雲南白藥33倍目標市盈率，目標股價112.0元。
風險包括：流通業務受兩票制影響；健康產品競爭激烈；混改效果不及預期。 
 
圖表：業務分部收入、增速及假設(RMB'000) 
 
2014
2015
2016
2017
2018E
2019E
營業收入
營業收入
營業收入
營業收入 
18,814,366.37 
20,738,126.21 
22,410,654.40 
24,314,614.04 
26,910,549.80 
29,263,000.50 
YOY
18.97%
10.22%
8.06%
8.50%
10.68%
8.74%
醫藥流通
醫藥流通
醫藥流通
醫藥流通 
10,588,189.27 
11,527,074.37 
13,275,890.44 
14,283,554.30 
15,283,403.10 
16,429,658.34 
YOY
18.01%
8.87%
15.17%
7.59%
7.00%
7.50%
GPM
6.54%
6.36%
7.84%
7.29%
Weight
56.28%
55.58%
59.24%
58.74%
56.79%
56.14%
醫藥工業
醫藥工業
醫藥工業
醫藥工業 
8,189,759.72 
9,180,400.94 
9,080,384.24 
9,962,024.66 
11,627,146.70 
12,833,342.17 
YOY
19.69%
12.10%
-1.09%
9.71%
16.71%
10.37%
GPM
60.65%
60.83%
62.10%
65.61%
63.86%
64.73%
--藥品事業部 
4,977,240.00 
5,095,940.00 
4,917,690.00 
5,043,510.00 
5,144,380.20 
5,272,989.71 
YOY
12.58%
2.38%
-3.50%
2.56%
2.00%
2.50%
Weight
26.45%
24.57%
21.94%
20.74%
19.12%
18.02%
--健康產品事業部
2,753,320.00 
3,354,510.00 
3,756,770.00 
4,361,150.00 
5,015,322.50 
5,817,774.10 
YOY
32.66%
21.84%
11.99%
16.09%
15.00%
16.00%
Weight
14.63%
16.18%
16.76%
17.94%
18.64%
19.88%
--中藥資源事業部
450,520.00 
651,400.00 
943,950.00 
1,162,870.00 
1,395,444.00 
1,660,578.36 
YOY
30.19%
44.59%
44.91%
23.19%
20.00%
19.00%
Weight
2.39%
3.14%
4.21%
4.78%
5.19%
5.67%
Source: Company, Phillip Securities 
 
圖表：同業比較 
毛利率
毛利率
毛利率
毛利率(%) 
淨利率
淨利率
淨利率
淨利率(%) 
市盈率
市盈率
市盈率
市盈率 
代碼
代碼
代碼
代碼 
總市值
總市值
總市值
總市值
/mn 
2017
2016
2015 
2017
2016
2015
TTM 
18E 
19E 
ROE 
(%) 
600518.SH 
110,826.4 
--
29.2 
27.6 
--
15.6 
15.4 
28.4 
22.5 
18.5 
--
000538.SZ 
101,515.6 
30.7 
29.4 
30.2 
13.0 
13.2 
13.4 
32.3 
27.0 
23.3 
18.6 
600436.SH 
53,852.1 
--
48.3 
46.4 
--
22.2 
24.8 
68.1 
53.6 
41.1 
--
600085.SH 
51,471.3 
45.7 
45.4 
45.5 
13.2 
13.1 
13.7 
50.6 
45.6 
40.2 
12.6 
600535.SH 
47,919.1 
35.5 
35.8 
38.2 
8.8 
8.8 
11.6 
34.8 
29.9 
25.8 
16.6 
600332.SH 
44,995.7 
37.1 
32.4 
35.6 
10.2 
7.9 
7.1 
22.8 
19.3 
17.0 
11.4 
600566.SH 
40,724.1 
--
85.0 
84.1 
--
20.4 
18.4 
35.0 
26.2 
21.1 
--
002773.SZ 
40,520.0 
--
90.2 
89.0 
--
20.1 
19.5 
62.9 
48.9 
38.2 
--
000423.SZ 
40,503.6 
64.6 
66.6 
64.2 
28.1 
29.7 
30.4 
19.8 
17.5 
15.5 
22.5 
603858.SH 
34,321.8 
--
82.8 
82.5 
--
14.7 
30.9 
20.9 
--
--
--
 
Highest 
110,826.4 
64.6 
90.2 
89.0 
28.1 
29.7 
30.9 
68.1 
53.6 
41.1 
22.5 
Median 
46,457.4 
37.1 
46.8 
46.0 
13.0 
15.1 
16.9 
33.5 
27.0 
23.3 
16.6 
Average 
56,665.0 
42.7 
54.5 
54.3 
14.6 
16.6 
18.5 
37.6 
32.3 
26.7 
16.3 
Source: Wind as at Apr 12th, Phillip Securities 
 
 
Page | 3 | PHILLISECURITIES (HK) RESEARCH 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ)
公司研報
公司研報
公司研報
公司研報 
 
財務報告
財務報告
財務報告
財務報告 
 
FYE 
FY2015
FY2016
FY2017
FY2018E
FY2019E
Valuation Ratios 
 
 
 
 
  
Price to Earnings (P/E) 
36.17 
34.36 
31.86 
28.34 
25.02 
Price to Book (P/B) 
7.46 
6.37 
5.56 
4.82 
4.21 
Per Share Data (RMB) 
 
 
 
 
  
EPS 
2.66 
2.80 
3.02 
3.40 
3.85 
Book Value Per Share 
12.90 
15.10 
17.32 
19.97 
22.85 
Dividend Per Share 
0.60 
0.80 
1.50 
1.70 
1.92 
Growth (%) 
 
 
 
 
  
Revenue 
10.22 
8.06 
8.50 
10.68 
8.74 
Gross Profit 
30.53 
29.86 
31.19 
31.89 
32.66 
Operating Income 
11.96 
4.78 
9.06 
12.89 
12.65 
Net Profit 
10.34 
6.36 
6.88 
12.87 
13.28 
Margins (%) 
 
 
 
 
  
Gross Profit Margin 
30.53 
29.86 
31.19 
31.89 
32.66 
Operating Profit Margin 
15.28 
14.81 
14.89 
15.19 
15.74 
Net Profit Margin 
13.29 
13.08 
12.88 
13.14 
13.69 
Profitability 
 
 
 
 
  
ROE (%) 
20.37 
18.50 
17.27 
17.00 
16.83 
ROA (%) 
14.28 
11.92 
11.31 
11.22 
11.11 
  
 
 
 
 
  
FYE 
FY2015
FY2016
FY2017
FY2018E
FY2019E
Income Statement (RMB Mn) 
 
 
 
  
Revenue 
20,738.1 
22,410.7 
24,314.6 
26,910.5 
29,263.0 
- Cost of Goods Sold 
-14,405.9 
-15,718.0 
-16,731.6 
-18,329.8 
-19,707.0 
Gross Income 
6,332.2 
6,692.7 
7,583.0 
8,580.7 
9,556.0 
- Operating Expenses 
-3,164.0 
-3,372.9 
-4,100.4 
-4,493.2 
-4,951.3 
Operating Income 
3,168.2 
3,319.8 
3,620.7 
4,087.5 
4,604.7 
+ Net Non-Operating Gain/Loss
47.1 
77.7 
1.1 
0.0 
0.0 
Pretax Income 
3,215.3 
3,397.5 
3,621.8 
4,087.5 
4,604.7 
- Income Tax Expenses 
-459.8 
-466.6 
-489.3 
-551.7 
-599.4 
- Minority Interest 
-15.3 
11.0 
-12.4 
-13.8 
-15.0 
Net Profit 
2,755.6 
2,930.9 
3,132.5 
3,535.8 
4,005.3 
Source: Company, Wind, Phillip Securities (HK) Research Estimates 
 (財務資料截至2018 年4 月13 日) 
  
 
 
 
 
 
 
 
PHILL
 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ)
公司研報
公司研報
公司研報
公司研報 
PHILLIP RESEARCH STOCK SELECTION SYSTEMS 
 
We do not base our recommendations entirely on the above quantitative return bands.  We consider qualitative factors like (but not limited to) a stock's 
risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones 
surrounding the stock, before making our final recommendation 
 
GENERAL DISCLAIMER 
This publication is prepared by Phillip Securities (Hong Kong) Ltd (“Phillip Securities”). By receiving or reading this publication, you agree to be bound by the terms and 
limitations set out below. 
 
This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or 
consequential loss arising from any use of material contained in this publication. 
 
The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, 
forecasts, projections, expectations and opinions (collectively the “Research”) contained in this publication are based on such information and are expressions of belief only. 
Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or 
verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any 
responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip 
Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even 
if it has been advised of the possibility of such damages. 
 
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without 
prior notice. 
 
This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any 
particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a 
financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, 
before making a commitment to invest in any of such products. 
This publication should not be relied upon as authoritative without further being subject to the recipient’s own independent verification and exercise of judgment. The fact 
that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in 
this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant 
risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are 
understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any 
product should not be considered to be a disclosure of all risks or a complete discussion of such risks. 
 
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research 
should take into account existing public information, including any registered prospectus in respect of such security. 
 
Disclosure of Interest 
Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this 
report. 
Firm’s Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or 
more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation. 
 
Availability 
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such 
distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or 
other requirement, or penalty for contravention of such requirements within such jurisdiction. 
 
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited (“PSHK”) believed to be accurate. PSHK does not bear responsibility for any 
loss occasioned by reliance placed upon the contents hereof.  PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of 
different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk.   
© 
2018 Phillip Securities (Hong Kong) Limited 
 
Contact Information (Regional Member Companies) 
Total Return 
Recommendation 
Rating 
Remarks 
>+20% 
Buy 
1 
>20% upside from the current price 
+5% to +20% 
Accumulate 
2 
+5% to +20%upside from the current price 
-5% to +5% 
Neutral 
3 
Trade within  ± 5% from the current price 
-5% to -20% 
Reduce 
4 
-5% to -20% downside from the current price 
<-20% 
Sell 
5 
>20%downside from the current price 
 
 
 
PHILL
 
雲南白藥
雲南白藥
雲南白藥
雲南白藥 (000538.SZ)
公司研報
公司研報
公司研報
公司研報 
SINGAPORE 
Phillip Securities Pte Ltd 
Raffles City Tower 
250, North Bridge Road #06-00 
Singapore 179101 
Tel : (65) 6533 6001 
Fax : (65) 6535 6631 
Website: www.poems.com.sg 
MALAYSIA 
Phillip Capital Management Sdn Bhd 
B-3-6 Block B Level 3 Megan Avenue II, 
No. 12, Jalan Yap Kwan Seng, 50450 
Kuala Lumpur 
Tel (603) 21628841 
Fax (603) 21665099 
Website: www.poems.com.my 
 
HONG KONG 
Phillip Securities (HK) Ltd 
Exchange Participant of the Stock Exchange of Hong Kong 
11/F United Centre 95 Queensway 
Hong Kong 
Tel (852) 22776600 
Fax (852) 28685307 
Websites: www.phillip.com.hk 
 
JAPAN 
PhillipCapital Japan K.K. 
Nagata-cho Bldg., 
8F, 2-4-3 Nagata-cho, 
Chiyoda-ku, Tokyo 100-0014 
Tel (81-3) 35953631 
Fax (81-3) 35953630 
Website:www.phillip.co.jp 
 
INDONESIA 
PT Phillip Securities Indonesia 
ANZ Tower Level 23B, 
Jl Jend Sudirman Kav 33A 
Jakarta 10220 – Indonesia 
Tel (62-21) 57900800 
Fax (62-21) 57900809 
Website:www.phillip.co.id 
 
CHINA 
Phillip Financial Advisory (Shanghai) Co. Ltd 
No 436 Hengfeng Road, 
Greentech Unit 604, 
Postal code 200070 
Tel (86-21) 51699400 
Fax (86-21) 63532643 
Website: www.phillip.com.cn 
 
THAILAND 
Phillip Securities (Thailand) Public Co. Ltd 
15th Floor, Vorawat Building, 
849 Silom Road, Silom, Bangrak, 
Bangkok 10500 Thailand 
Tel (66-2) 6351700 / 22680999 
Fax (66-2) 22680921 
Websitewww.phillip.co.th 
 
FRANCE 
King & Shaxson Capital Limited 
3rd Floor, 35 Rue de la Bienfaisance 75008 
Paris France 
Tel (33-1) 45633100 
Fax (33-1) 45636017 
Website: www.kingandshaxson.com 
 
UNITED KINGDOM 
King & Shaxson Capital Limited 
6th Floor, Candlewick House, 
120 Cannon Street, 
London, EC4N 6AS 
Tel (44-20) 7426 5950 
Fax (44-20) 7626 1757 
Website: www.kingandshaxson.com 
 
UNITED STATES 
Phillip Futures Inc 
141 W Jackson Blvd Ste 3050 
The Chicago Board of Trade Building 
Chicago, IL 60604 USA 
Tel +1.312.356.9000 
Fax +1.312.356.9005 
 
AUSTRALIA 
PhillipCapital Australia 
Level 12, 15 William Street, 
Melbourne, Victoria 3000, Australia 
Tel (613) 96188238 
Fax (613) 92002272 
Website: www.phillipcapital.com.au 
 
 
